Bridge Biotherapeutics, Inc. and Boehringer Ingelheim GmbH have agreed to terminate their collaboration and license agreement reached in July 2019 to develop BBT-877, a small molecule inhibitor of autotaxin, for the treatment of idiopathic pulmonary fibrosis (IPF) and various other fibrotic diseases.
The decision is a setback for both companies as the South Korean biotech will now have to determine the fate of its lead asset, while the big German multinational may...